Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL
January 19th 2023A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.
Read More
Interstitial Lung Abnormalities Impact OS in NSCLC Patients Receiving CRT, Adjuvant Durvalumab
January 19th 2023Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.
Read More
Adding Social Factors to Risk Adjustment Not Enough to Reach Health Equity, Paper Says
January 12th 2023To best improve health equity, population-based payment models should both incorporate social goals and increase payment for historically marginalized communities, a recent study has found.
Read More
Distinct Molecular Profiles in Younger vs Older Patients With MDS Identified in New Study
December 25th 2022The relationship between aging and molecular profiles in myelodysplastic syndromes (MDS) is not well understood, but the findings suggest that different genetic alterations have distinct prognostic implications in different age groups.
Read More
ASXL1 Mutations Associated With Worse Prognosis in MDS and AML
December 18th 2022A recent meta-analysis found ASXL1 mutations to be independent risk factors for worse overall survival and transformation to acute myeloid leukemia in patients with myelodysplastic syndromes (MDS), as well as worse overall survival in acute myeloid leukemia (AML).
Read More
Post Hoc Analysis of IMPACT Trial Finds Triplet Regimen Effective in COPD
December 2nd 2022The findings suggest that treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) led to improvements and had a similar safety profile to both FF/VI and UMEC/VI regardless of patient chronic mucus hypersecretion status at baseline.
Read More
Genealogical Study of Primary Ovarian Insufficiency Suggests Strong Genetic Component
December 2nd 2022The population-level, mutigenerational study found that both near and distant relatives of women with primary ovarian insufficiency were at a higher risk of the condition compared with matched controls.
Read More
CBD May Improve Neurologic, Cognitive, QOL Outcomes in Sturge-Weber Syndrome
November 28th 2022A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.
Read More
Nirmatrelvir-Ritonavir Shows Safety, Efficacy in Real-world Study of High-risk COVID-19 Patients
November 23rd 2022The retrospective study evaluated outcomes in patients prescribed nirmatrelvir-ritonavir, as well as the management of drug interactions by clinical pharmacists prescribing the regimen.
Read More
Exploring Current Eosinophilic Gastrointestinal Disease Nomenclature and Management
November 23rd 2022An article published in the journal Gastroenterology & Hepatology highlights recent updates to eosinophilic gastrointestinal disease nomenclature, as well as updates related to diagnosis, pathogenesis, and treatment standards.
Read More
New Clinical Guidelines Recommend Finerenone for CKD Associated With T2D
November 21st 2022Updated Kidney Disease: Improving Global Outcomes guidelines and a consensus report with the American Diabetes Association support the use of finerenone in certain patients who have chronic kidney disease (CKD) that may be linked to type 2 diabetes (T2D).
Read More